A childhood cancer diagnosis forces families into decisions that feel urgent and unclear. Neuroblastoma is the most common solid tumour outside the brain in infants, and it still accounts for about 15 per cent of cancer deaths in children. Knowing whether a tumour can be removed safely often matters as much as naming the disease.
Doctors Andrew Sung, Elyssa Rubin and Hollie Lai, working at Children’s Hospital of Orange County, reviewed how scan findings can mark that surgical risk before an operation begins. Their review was published in the Journal of the American Osteopathic College of Radiology. It explains a staging approach built around image-defined risk factors, features on scans linked to a higher chance of complications if surgeons try to remove the tumour at once.
Neuroblastoma arises from immature nerve cells along the sympathetic chain. The median age at diagnosis is about 16 months, and about 95% of cases are found by the age of seven. Common sites include the adrenal glands, the area behind the abdominal organs, and the back of the chest.
Some tumours shrink on their own. Others spread and remain hard to cure, with event-free survival in metastatic disease still around 60 per cent at three years even with intensive treatment. That range of outcomes is why staging has to do more than describe size.
Older staging depended heavily on what surgeons found in the operating theatre. That made it difficult to compare patients before treatment, because the result depended on the operation itself. The International Neuroblastoma Risk Group system, set out in 2009, shifted the judgement earlier.
A localised tumour without an image-defined risk factor is classed as L1. A tumour with one or more of those features is L2. Distant spread is stage M, while a separate stage, MS, covers limited spread to skin, liver or bone marrow in children younger than 18 months.
The risky features are practical rather than abstract. A tumour that wraps around more than half of a major artery, flattens a vein until the channel disappears, squeezes an airway, or grows into a neighbouring organ counts as positive. Contact with the vessels of the kidney is treated as invasion, because removal can force loss of the kidney or damage part of it.
Tumour crossing two body regions, such as chest and abdomen, is also treated as higher risk. So is growth that fills more than a third of the spinal canal. These details come from contrast CT or MRI, which the staging system treats as essential for childhood neuroblastoma imaging.
Ultrasound is often the first test when a parent or doctor feels a mass, and it avoids radiation and sedation. It is not enough to judge these risk factors. CT is quick and shows airway narrowing clearly, while MRI shows soft tissue and spinal canal extension more clearly, though young children often need sedation.
A specialist nuclear medicine scan, using MIBG, looks for spread and is taken up by about 90 per cent of these tumours. For parents, the label on a scan report is a map of what stands in the way of a safe operation. Teams may choose chemotherapy first to shrink a risky tumour rather than operate at once.
